Page 25 - Micro Caps News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Energy Fuels receives another US$1.75M from US Department of Energy for rare earth feasibility study The firm believes it can design its infrastructure to process feeds produced in the DoE program as well as the Monazite it is currently processing, for the recovery of uranium and REE products The award comes after the DoE gave Energy Fuels a $150,000 contract last year to complete a conceptual design for the initiative Energy Fuels Inc (NYSE:UUUU) (TSE:EFR) (FRA:VO51) and a team from Penn State University have been awarded another US$1.75 million by the US Department of Energy (Do...

Follow Andrew on: Tetra Bio-Pharma ships inhaled cannabis drug QIKLEEF to US ahead of opioid comparision study in patients with breakthrough cancer pain REBORN1 will evaluate cannabis as an alternative to morphine sulfate immediate release, an opioid, in the management of breakthrough pain Tetra Bio-Pharma has completed the manufacturing of QIXLEEF and received the necessary cannabis export permit from Health Canada Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) said it has shipped its investigational new drug, QIXLEEF, to the US to initiate the planned REBORN1 study of p...

NA Proactive news snapshot: One World Lithium, Recruiter.com Group, Aion Therapeutic, Nextleaf Solutions, Phyto Extractions UPDATE … A glance at some of the day's highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive One World Lithium Inc (CSE:OWLI) (OTCMKTS:OWRDF) announced it had started drilling the third hole of a four-hole drill program as part of its Phase Three program at the Salar del Diablo lithium brine property in Mexico. Drilling at DDH-3 (diamond drill hole) will occur 24 hours a day, the company said in a re...

Lexaria Bioscience says dosing in first human trial of DehydraTECH CBD to treat high blood pressure has started It is the first of three clinical trials aimed at assessing this potential treatment, and dosing of human volunteers has begun The first trial is a randomized, double-blinded, controlled human clinical study expected to involve 24 volunteers with symptoms of either pre-hypertension or mild hypertension Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) revealed that its first human clinical trial assessing its DehydraTECH CBD technology to treat high blood pressure - HYPER...

The cannabis company generated about $543,000 in single-day sales on April 20, with gross margins during the month in excess of 50%